Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV, Pancreatic Ductal Adenocarcinoma, Pancreatic Neoplasms
Conditions
Keywords
Pancreas, Cancer, Biomarker
Brief summary
Aberrant miRNA production has been linked to a wide range of human cancers and shown to play important roles in their genesis and growth. These miRNA can be detected in the blood and tumors of patients with cancer. The investigators hypothesize that the detection of certain miRNAs present in the blood/serum of patients with pancreatic cancer may be important to the early diagnosis of the disease. Furthermore, the investigators hypothesize that miRNA detection in PC patients will yield prognostic information and help predict the response to treatment.
Detailed description
Specific aims of the study include: 1. To obtain serum samples from patients with newly diagnosed pancreatic cancer at baseline before treatment and monthly throughout treatment. 2. To analyze the miRNA profiles present at each time point. 3. To determine miRNAs that may distinguish pancreatic patients from unaffected individuals. This could be developed into a diagnostic test. 4. To determine miRNAs whose levels correlate with treatment response, both in patients with and without elevations in the serum tumor marker CA 19-9.
Interventions
PROCEDUREBlood draw
Individuals in the unresectable pancreatic cancer group will receive monthly blood draws. Individuals in the control group will receive one blood draw
Sponsors
Nuvance Health
Study design
Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Have biopsy proven adenocarcinoma of the pancreas * Have initially inoperable disease, classified as either locally advanced or metastatic disease * Recurrent disease after a Whipple procedure is allowed * Patients who are able to undergo resection after neoadjuvant therapy will continue to be followed after resection * Have radiographically measurable disease * Have an ECOG performance status of 2 or less * Be willing to contribute the required information and specimens * Provide written signed consent to participate
Exclusion criteria
* Having received prior anti-cancer treatments for metastatic pancreatic cancer * Concurrently receiving systemic therapy for another cancer except androgen deprivation therapy for stable/controlled prostate cancer * Presence of other active cancer except for: adequately treated local basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate-specific antigen for \>1 year prior to start of trial. Other adequately treated Stage 1 or 2 cancer currently in complete remission, or any other cancer that has been in complete remission for \> 5 years is allowable
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Analysis of miRNA profile | Through study completion, up to 5 years | Analyze the miRNA profiles present at each time point. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PCR miRNA validation | Through study completion, up to 5 years | Determine miRNAs that may distinguish pancreatic patients from unaffected individuals. This could be developed into a diagnostic test. |
| miRNA PCR expression | Through study completion, up to 5 years | Determine miRNAs whose levels correlate with treatment response, both in patients with and without elevations in the serum tumor marker CA 19-9. |
Countries
United States
Contacts
CONTACTPramila Krumholtz, RN
CONTACTTammy Lo, MSN
PRINCIPAL_INVESTIGATORRichard Frank, MD
Nuvance Health
Outcome results
None listed